ACM
PTGX icon

ADAR1 Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

ADAR1 Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-132,000
Closed -$5.1M – 240
2024
Q4 		$5.1M Buy
+132,000
New +$5.75M 1.02% 23

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

ADAR1 Capital Management's PTGX Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 5.2% in Q1 2026, selling an estimated $4.87M and leaving 994,119 shares worth $105M. The position accounts for 6.17% of the portfolio, ranked #2.

ADAR1 Capital Management first reported a position in PTGX in Q4 2023 and has held it in 10 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • ADAR1 Capital Management held 994,119 shares of Protagonist Therapeutics worth $105M as of Q1 2026.
  • ADAR1 Capital Management sold 55,049 Protagonist Therapeutics shares in Q1 2026, an estimated $4.87M.
  • Protagonist Therapeutics made up 6.17% of ADAR1 Capital Management's portfolio in Q1 2026, its #2 holding.
  • ADAR1 Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.